TATA Health (1255) Announces Completion of Resumption Requirements and Trading Resumption

Bulletin Express
2025/11/28

Hong Kong-listed TATA Health International Holdings Limited (Stock code: 1255) has announced that it has fulfilled all resumption guidance issued by the Stock Exchange of Hong Kong. Trading in its shares, which had been suspended since 2 April 2024, is set to resume on 1 December 2025.

TATA Health clarified that it has published all outstanding financial reports, including annual and interim results from 2023 to 2025, and addressed related audit concerns. The company further indicated that any remaining audit modifications are expected to be fully removed by fiscal year 2027 without ongoing effects on its future consolidated statements. According to the announcement, management has also confirmed sufficient working capital for at least the next 18 months.

A key part of TATA Health’s resumption plan involved re-focusing on its core footwear business and divesting certain loss-making healthcare, financial services, and online medical services segments. The company now operates two principal footwear models—a long-standing distributorship arrangement and a retail-as-a-service framework with an external partner—to streamline costs and improve operational efficiency. Management projects continued revenue growth, citing a potential memorandum of understanding with a global French fashion brand to broaden the company’s product portfolio and geographic footprint.

In addition to commercial restructuring, TATA Health re-established its board and committee composition to meet Listing Rule requirements. Several directors and executives were appointed or re-designated, ensuring compliance with governance standards regarding independent directors and committee memberships. An independent consultancy also completed an internal control review, leading to further enhancements in corporate governance and risk management.

Having satisfied the Stock Exchange’s conditions and issued multiple updates regarding board changes, financial audits, and operational developments, TATA Health has confirmed it will resume trading, with management underscoring that current business and governance structures meet the relevant listing obligations.

免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。

热议股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10